Next report date
Report period
H1 2024
EPS estimate
−1.67USD
Revenue estimate
2.53 MUSD
−3.71USD
−159.72 MUSD
55.01 M
About ABIVAX
Sector
CEO
Marc M. P. de Garidel
Headquarters
Paris
Website
Employees (FY)
61
Founded
2013
FIGI
BBG01JLQNZ03
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
